Home Endocrinology & Hormones Glucocorticoid Receptor agonist Mometasone furoate

research use only

Mometasone furoate Glucocorticoid Receptor agonist

Cat.No.S1987

Mometasone Furoate (SCH-32088,mometasone 17-furoate) is a glucocorticoid receptor agonist, used topically to reduce inflammation of the skin or in the airways.
Mometasone furoate Glucocorticoid Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 521.43

Jump to

Quality Control

Batch: S198701 DMSO]6 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.57%
99.57

Solubility

In vitro
Batch:

DMSO : 6 mg/mL (11.5 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 521.43 Formula

C27H30Cl2O6

 Storage (From the date of receipt)
CAS No. 83919-23-7 Download SDF Storage of Stock Solutions

Synonyms SCH-32088,mometasone 17-furoate SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
Glucocorticoid receptor
In vitro

Mometasone furoate efficiently suppresses production of cytokines including interleukin (IL)-4, IL-5, and interferon-gamma in anti-CD3-stimulated human CD4+ T cells. This compound effectively inhibits the activation of Th cells including type 2 Th (Th2) in the draining LN, thus leading to the suppression of the IgE response.

In vivo

Mometasone furoate causes a decrease in the instances of nasal rubbing and an inhibition of this response is observed during the treatment period in rats. This compound (3 mg/kg) inhibits the increased airway sensitivity to aerosolized methacholine at the highest dose tested in mice. It, given an hour after the last allergen challenge, dose-dependently inhibits the allergen-induced increase in Penh with about a 10-fold loss of potency when compared with the pre-challenge treatment schedule. This chemical (0.02%) and fluticasone propionate (0.1%) significantly inhibits the increase of antigen-induced nasal rubbing even 6 hours after topical application, indicating that both drugs have a long-lasting effect. It dose-dependently inhibits the elevated eosinophil numbers in the bronchoalveolar lavage fluid and lung tissues of sensitized, ovalbumin challenged mice. This compound (33 mg/kg) reduces the percentage of CD44+ T-helper cells (activated/memory cells) to the levels observed in non-sensitized, ovalbumin-challenged mice.

References
  • [4] https://pubmed.ncbi.nlm.nih.gov/10940782/
  • [5] https://pubmed.ncbi.nlm.nih.gov/9608881/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2022-04-27)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05348148 RECRUITING
Allergic Rhinitis; Vasomotor Rhinitis
Camillians Saint Mary's Hospital Luodong
 2020-06-16
NCT06914908 ENROLLING_BY_INVITATION
Chronic Rhinosinusitis With Nasal Polyps
Sanofi
 2025-05-12 PHASE2
NCT05776927 RECRUITING
Asthma
Novartis Pharmaceuticals
 2026-08-04 PHASE3
NCT05562466 RECRUITING
Asthma
Novartis Pharmaceuticals
 2023-05-11 PHASE3
NCT06399783 NOT_YET_RECRUITING
Alopecia Areata
Assiut University
 2024-10-01 PHASE4
NCT07787494 NOT_YET_RECRUITING
Chronic Rhinosinusitis (CRS)
Liaquat University of Medical & Health Sciences
 2026-09-07

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.